PO:36:243 | Drug survival, discontinuation reasons and disease activity in patients with Behçet’s disease treated with infliximab - a real-life study: Antonello Sulis1, Federica Di Cianni1, Maria Laura Manca2, Rosaria Talarico1, Marta Mosca1. | 1Rheumatology Unit of Pisa, University of Pisa, Pisa, Italy, Pisa, Italy; 2Department of Clinical and Experimental Medicine and Department of Mathematics, University of Pisa, Italy, Pisa, Italy. Reumatismo [Internet]. 2025 Nov. 25 [cited 2026 Jun. 27];77(s1). Available from: https://www.reumatismo.org/reuma/article/view/2091